

Hongsheng Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9930193/publications.pdf>

Version: 2024-02-01

58
papers

479
citations

840776

11
h-index

713466

21
g-index

59
all docs

59
docs citations

59
times ranked

1003
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 97-104.	2.0	145
2	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. <i>Cell Research</i> , 2018, 28, 172-186.	12.0	62
3	Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 43.	8.6	42
4	Identification of Novel Molecular Markers for Prognosis Estimation of Acute Myeloid Leukemia: Over-Expression of PDCD7, FIS1 and Ang2 May Indicate Poor Prognosis in Pretreatment Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e84150.	2.5	33
5	Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. <i>Oncotarget</i> , 2016, 7, 32579-32591.	1.8	31
6	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. <i>Leukemia</i> , 2021, 35, 1380-1391.	7.2	26
7	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. <i>Oncolmmunology</i> , 2016, 5, e1139274.	4.6	24
8	Antifungal Agents for Secondary Prophylaxis Based on Response to Initial Antifungal Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1198-1203.	2.0	21
9	A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110390.	5.6	17
10	Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor. <i>Oncotarget</i> , 2017, 8, 26505-26514.	1.8	14
11	Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway. <i>Oncology Reports</i> , 2016, 36, 1626-1632.	2.6	12
12	Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 11409-11420.	1.8	10
13	Early T-Cell Precursor Leukemia Has a Higher Risk of Induction-Related Infection among T-Cell Acute Lymphoblastic Leukemia in Adult. <i>Mediators of Inflammation</i> , 2020, 2020, 1-10.	3.0	8
14	Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia. <i>Oncology Letters</i> , 2018, 15, 917-925.	1.8	7
15	A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4011-4011.	1.4	5
16	Analysis of Infection-Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Refractory/Relapse Acute Leukemia. <i>Blood</i> , 2012, 120, 4513-4513.	1.4	4
17	Combination of Homoharringtonine with Venetoclax and Azacitidine Exerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	1.4	4
18	Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia. <i>Cancer Letters</i> , 2021, 510, 59-66.	7.2	2

#	ARTICLE	IF	CITATIONS
19	Autologous HSCT Followed By Immunotherapy and Maintenance Chemotherapy Compared with Allogeneic HSCT for Intermediate-Risk Molecules/Cytogenetics Acute Myeloblastic Leukemia in First Complete Remission. <i>Blood</i> , 2014, 124, 3949-3949.	1.4	2
20	HDACi Targets IKZF1 Deletion High-Risk Acute Lymphoblastic Leukemia By Inducing IKZF1 Expression and Rescuing IKZF1 Function in Vitro and In Vivo. <i>Blood</i> , 2021, 138, 514-514.	1.4	2
21	Mesenchymal Stem Cells Vs. Mesenchymal Stem Cells Combined With Cord Blood For Treating Engraftment Failure Following Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective Study. <i>Blood</i> , 2013, 122, 3693-3693.	1.4	1
22	Continuous intravenous injection of Mesna can effectively prevent Hemorrhagic cystitis in hematopoietic stem cell transplantation and retain the Mesna's concentration in urine: 394 cases reported within 11 years. <i>Blood</i> , 2014, 124, 2483-2483.	1.4	1
23	The Management of EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 1959-1959.	1.4	1
24	Emerging Potential Roles of Lysyl-Oxidase-like 2 Stimulates Cancer Associated Fibroblasts Promoting Myelofibrosis of Myeloproliferative Neoplasms. <i>Blood</i> , 2016, 128, 5495-5495.	1.4	1
25	Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Blood</i> , 2011, 118, 4938-4938.	1.4	0
26	Continuous Intravenous Injection of Mesna Is Powerful in Preventing Acute Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation: 108 Cases report. <i>Blood</i> , 2011, 118, 3015-3015.	1.4	0
27	Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Cdh1 in Blast Crisis of Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 4428-4428.	1.4	0
28	Antithymocyte Globulin (ATG) Plus Cyclosporine (CsA) and Combined with Cord Blood Infusion Is Superior to ATG Plus Csa for the Treatment of Severe Aplastic Anemia. <i>Blood</i> , 2012, 120, 4397-4397.	1.4	0
29	Effect of Antithymocyte Globulin Dosage for Prophylactic Gvhd On Epstein-Barr Virus Reactivation and Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4486-4486.	1.4	0
30	Molecular Monitoring and Stepwise Preemptive Therapy to Prevent Epstein-Barr Virus-Associated Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3067-3067.	1.4	0
31	Secondary Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients. <i>Blood</i> , 2012, 120, 4140-4140.	1.4	0
32	The Comparison Between Long-Term and Short-Term Administration of Itraconazole for Primary Antifungal Prophylaxis in Recipients of Allogeneic Hematopoietic Stem Cell: A Multicenter, Randomized, Open-Label Trial (NCT01160952). <i>Blood</i> , 2012, 120, 1930-1930.	1.4	0
33	Improvement in Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation Upon Administration of Mesenchymal Stem Cells From Third-Party Donors: A Pilot Prospective Study. <i>Blood</i> , 2012, 120, 1904-1904.	1.4	0
34	Herpesvirus-Associated Central Nervous System Diseases After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4139-4139.	1.4	0
35	Epstein-Barr Virus Infection In Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation: The Role Of Cytomegalovirus. <i>Blood</i> , 2013, 122, 4555-4555.	1.4	0
36	Mesenchymal Stem Cell As a Salvage Treatment For Refractory Acute Graft-Versus-Host Disease: a Matched Pair Analysis. <i>Blood</i> , 2013, 122, 3294-3294.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Continuous Intravenous Injection Of Mesna Can Reduce Acute Hemorrhagic Cystitis Occurrence Rate In Hematopoietic Stem Cell Transplantation: 359 Allo-HSCT Cases Report. <i>Blood</i> , 2013, 122, 4556-4556.	1.4	0
38	Sequential Intensified Conditioning Followed By Early Tapering Immunosuppressants and DLI In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory/Recurrent T Lymphoblastic Lymphoma. <i>Blood</i> , 2013, 122, 2122-2122.	1.4	0
39	Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies. <i>Blood</i> , 2013, 122, 5509-5509.	1.4	0
40	Sequential Intensified Conditioning Followed By Tapering Of Prophylactic Immunosuppressants and Donor Lymphocyte Infusions In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory Leukemia. <i>Blood</i> , 2013, 122, 702-702.	1.4	0
41	Molecular Mechanism Of Regulation Of Extramedullary Infiltration In AML1/ETO Positive Acute Myeloid Leukemia By APP/ERK/MMP-2. <i>Blood</i> , 2013, 122, 3769-3769.	1.4	0
42	Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission. <i>Blood</i> , 2013, 122, 3290-3290.	1.4	0
43	Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Chronic Myeloid Leukemia In Chronic Phase. <i>Blood</i> , 2013, 122, 5518-5518.	1.4	0
44	Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4637-4637.	1.4	0
45	HLA Polymorphisms and Epstein-Barr Virus Infection In The Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3291-3291.	1.4	0
46	The E3 Ubiquitin Ligases Siah2 Contributes To Imatinib Resistance In Chronic Myeloid Leukemia In Hypoxia Condition. <i>Blood</i> , 2013, 122, 2530-2530.	1.4	0
47	The Prevalent, Features and Prognostic Impact of Deletion p16 in Patients with Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5351-5351.	1.4	0
48	Role of Allogeneic Hematopoietic Stem Cell Transplantation for None Remission / Advanced Acute Myeloid Leukemia with Flt3-ItD Mutations: Outcomes of 15 Newly Diagnosed Patients from a Single Institution. <i>Blood</i> , 2014, 124, 5936-5936.	1.4	0
49	New Insight into Epstein-Barr Virus-Associated Biological Behavior of Aggressive Natural Killer Cell Leukemia. <i>Blood</i> , 2014, 124, 3002-3002.	1.4	0
50	Role of Surgical Resection in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis. <i>Blood</i> , 2014, 124, 5846-5846.	1.4	0
51	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: Comparison of Outcomes Among HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors and HLA-Mismatched Family Donors. <i>Blood</i> , 2014, 124, 5917-5917.	1.4	0
52	Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study. <i>Blood</i> , 2015, 126, 4352-4352.	1.4	0
53	Synergistic Effects of Combined Targeting of Beta-Catenin/CBP and Bcr-Abl in CML Blast Crisis Stem/Progenitor Cells in Vitro and in Vivo as Analyzed By Single Cell Mass Cytometry (CyTOF). <i>Blood</i> , 2015, 126, 1566-1566.	1.4	0
54	APP Gene Involves in the Regulation of Cell Apoptosis in AML1-ETO-Positive Leukemia Via SCF/c-Kit Signaling Pathway. <i>Blood</i> , 2015, 126, 3647-3647.	1.4	0

#	ARTICLE	IF	CITATIONS
55	A Comparison of Lamivudine and Entecavir for the Prophylaxis of Hepatitis B Virus Reactivation in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institutional Experience. Blood, 2015, 126, 2026-2026.	1.4	0
56	Efficacy and Safety of Micafungin As Salvage Treatment for Invasive Fungal Disease in Patients with Hematologic Malignancies. Blood, 2015, 126, 4628-4628.	1.4	0
57	Autoimmune Hematological Diseases Following Haploidentical Donor Hematopoietic Stem Cell Transplant Compared with Matched Sibling and Unrelated Donor. Blood, 2016, 128, 5861-5861.	1.4	0
58	IKZF1 deletions Coupled with CD20 Expression Represents a Novel High-Risk Subtype in Adult B-Cell Progenitor Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4474-4474.	1.4	0